{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T13:11:40Z","timestamp":1788613900607,"version":"build-2803163510"},"reference-count":31,"publisher":"BMJ","issue":"9","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2026,8,26]]},"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:p>Evans syndrome is a rare autoimmune disorder characterised by concurrent or sequential autoimmune haemolytic anaemia and immune thrombocytopenia, often posing significant diagnostic and therapeutic challenges due to its relapsing nature and variable response to treatment. We report a patient with severe Evans syndrome who developed status epilepticus in the setting of intracranial haemorrhage secondary to profound treatment-refractory thrombocytopenia, illustrating the potential for life-threatening neurological complications when cytopenias are uncontrolled. Despite limited improvement with first-line therapies, the patient experienced haematologic recovery and clinical stabilisation following initiation of avatrombopag, a thrombopoietin receptor agonist. This case highlights the importance of early recognition of treatment refractoriness and supports the emerging role of avatrombopag as a valuable therapeutic option for persistent thrombocytopenia in Evans syndrome.<\/jats:p>","DOI":"10.1136\/bcr-2026-273206","type":"journal-article","created":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T12:15:16Z","timestamp":1788610516000},"page":"e273206","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Neurologic complications of Evans syndrome"],"prefix":"10.1136","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9194-3220","authenticated-orcid":false,"given":"Rina R","family":"Thaker","sequence":"first","affiliation":[{"name":"Norwalk Hospital, Norwalk, Connecticut, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed","family":"Aquily","sequence":"additional","affiliation":[{"name":"Norwalk Hospital, Norwalk, Connecticut, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luisa","family":"Ladel","sequence":"additional","affiliation":[{"name":"Norwalk Hospital, Norwalk, Connecticut, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,9,5]]},"reference":[{"key":"2026090505151136000_19.9.e273206.1","doi-asserted-by":"crossref","unstructured":"Jiang Debbie . Evans syndrome revisited . Sciencedirect, 2025.","DOI":"10.1016\/j.blre.2025.101322"},{"key":"2026090505151136000_19.9.e273206.2","unstructured":"Shaikh H . Evans syndrome. In: StatPearls. U.S. National Library of Medicine, 2023."},{"key":"2026090505151136000_19.9.e273206.3","doi-asserted-by":"crossref","DOI":"10.3390\/jcm9123851","article-title":"Evans\u2019 Syndrome: From Diagnosis to Treatment","volume":"9","author":"Audia","year":"2020","journal-title":"J Clin Med"},{"key":"2026090505151136000_19.9.e273206.4","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2008.01206.x"},{"key":"2026090505151136000_19.9.e273206.5","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2005.05809.x"},{"key":"2026090505151136000_19.9.e273206.6","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1111\/jth.13019","article-title":"Severe bleeding events in adults and children with primary immune thrombocytopenia: a systematic review: reply","volume":"13","author":"Neunert","year":"2015","journal-title":"J Thromb Haemost"},{"key":"2026090505151136000_19.9.e273206.7","doi-asserted-by":"publisher","DOI":"10.1097\/00043426-200308000-00017"},{"key":"2026090505151136000_19.9.e273206.8","doi-asserted-by":"crossref","first-page":"66","DOI":"10.37080\/nmj.76","article-title":"Intracranial Haemorrhage as a Fatal Complication of Evans Syndrome: A Case Report","volume":"2","author":"Shilpakar","year":"2020","journal-title":"Nepal Med Jor"},{"key":"2026090505151136000_19.9.e273206.9","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-021-10439-3"},{"key":"2026090505151136000_19.9.e273206.10","doi-asserted-by":"publisher","DOI":"10.1007\/s12028-007-0056-2"},{"key":"2026090505151136000_19.9.e273206.11","unstructured":"Giannotta JA . Intravenous immunoglobulins in autoimmune cytopenias: an old tool with an alternative dosing schedule. Blood Transfusion, US National Library of Medicine, 2023."},{"key":"2026090505151136000_19.9.e273206.12","doi-asserted-by":"publisher","DOI":"10.1182\/hematology.2025000719"},{"key":"2026090505151136000_19.9.e273206.13","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-007-0317-3"},{"key":"2026090505151136000_19.9.e273206.14","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances"},{"key":"2026090505151136000_19.9.e273206.15","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1111\/bjh.13827","article-title":"Remission and platelet responses with romiplostim in primary immune thrombocytopenia: final results from a phase 2 study","volume":"172","author":"Newland","year":"2016","journal-title":"Br J Haematol"},{"key":"2026090505151136000_19.9.e273206.16","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1159\/000521689","article-title":"Romiplostim for Primary Immune Thrombocytopenia in Routine Clinical Practice: Results from a Multicentre Observational Study in Germany","volume":"145","author":"Reiser","year":"2022","journal-title":"Acta Haematol"},{"key":"2026090505151136000_19.9.e273206.17","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1177\/1078155217748470","article-title":"Initial romiplostim dosing and time to platelet response in patients with treatment refractory immune thrombocytopenia","volume":"25","author":"DasGupta","year":"2019","journal-title":"J Oncol Pharm Pract"},{"key":"2026090505151136000_19.9.e273206.18","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.1053\/j.seminhematol.2013.03.005","article-title":"Thrombopoietin receptor agonists in primary immune thrombocytopenia","volume":"50 Suppl 1","author":"Siegal","year":"2013","journal-title":"Semin Hematol"},{"key":"2026090505151136000_19.9.e273206.19","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1182\/blood.2022016818","article-title":"Thrombopoietin receptor agonists in adult Evans syndrome: an international multicenter experience","volume":"140","author":"Fattizzo","year":"2022","journal-title":"Blood"},{"key":"2026090505151136000_19.9.e273206.20","doi-asserted-by":"crossref","first-page":"2040620719837906","DOI":"10.1177\/2040620719837906","article-title":"Switching thrombopoietin receptor agonist treatments in patients with primary immune thrombocytopenia","volume":"10","author":"Gonz\u00e1lez-Porras","year":"2019","journal-title":"Ther Adv Hematol"},{"key":"2026090505151136000_19.9.e273206.21","doi-asserted-by":"crossref","unstructured":"Bussel J . A randomized trial of avatrombopag, an investigational thrombopoietin-receptor agonist, in persistent and chronic immune thrombocytopenia | blood | American Society of Hematology. American Society of Hematology, 2014.","DOI":"10.1182\/blood-2013-07-514398"},{"key":"2026090505151136000_19.9.e273206.22","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.32143","article-title":"Real-World Use of Avatrombopag in Children and Adolescents With Immune Thrombocytopenia","volume":"73","author":"Harris","year":"2026","journal-title":"Pediatr Blood Cancer"},{"key":"2026090505151136000_19.9.e273206.23","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1111\/ejh.14395","article-title":"Avatrombopag for the Treatment of Immune Thrombocytopenia","volume":"114","author":"Labanca","year":"2025","journal-title":"Eur J Haematol"},{"key":"2026090505151136000_19.9.e273206.24","unstructured":"AMGEN . Romiplostim Dosing and Titration Guide. 2026. Available: https:\/\/www.nplatehcp.com\/dosing"},{"key":"2026090505151136000_19.9.e273206.25","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1007\/s00277-023-05114-8","article-title":"Use of thrombopoietin receptor agonists in adults with immune thrombocytopenia: a systematic review and Central European expert consensus","volume":"102","author":"Pulani\u0107","year":"2023","journal-title":"Ann Hematol"},{"key":"2026090505151136000_19.9.e273206.26","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1111\/bjh.13266","article-title":"Use of eltrombopag after romiplostim in primary immune thrombocytopenia","volume":"169","author":"Gonz\u00e1lez\u2010Porras","year":"2015","journal-title":"Br J Haematol"},{"key":"2026090505151136000_19.9.e273206.27","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1002\/ajh.24935","article-title":"Alternate use of thrombopoietin receptor agonists in adult primary immune thrombocytopenia patients: A retrospective collaborative survey from Italian hematology centers","volume":"93","author":"Cantoni","year":"2018","journal-title":"Am J Hematol"},{"key":"2026090505151136000_19.9.e273206.28","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2012.074633"},{"key":"2026090505151136000_19.9.e273206.29","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1111\/ejh.12932","article-title":"Thrombopoietin receptor agonist switch in adult primary immune thrombocytopenia patients: A retrospective collaborative survey involving 4 Spanish centres","volume":"99","author":"Lakhwani","year":"2017","journal-title":"Eur J Haematol"},{"key":"2026090505151136000_19.9.e273206.30","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1111\/bjh.18081","article-title":"Adults with immune thrombocytopenia who switched to avatrombopag following prior treatment with eltrombopag or romiplostim: A multicentre US study","volume":"197","author":"Al-Samkari","year":"2022","journal-title":"Br J Haematol"},{"key":"2026090505151136000_19.9.e273206.31","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s12185-014-1731-7","article-title":"Treatment patterns and clinical outcomes in patients with chronic immune thrombocytopenia (ITP) switched to eltrombopag or romiplostim","volume":"101","author":"Kuter","year":"2015","journal-title":"Int J Hematol"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2026-273206","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T12:15:18Z","timestamp":1788610518000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2026-273206"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":31,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9,5]]},"published-print":{"date-parts":[[2026,9]]}},"alternative-id":["10.1136\/bcr-2026-273206"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2026-273206","relation":{},"ISSN":["1757-790X"],"issn-type":[{"value":"1757-790X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9]]}}}